Cardiff Oncology Inc. (CRDF)

Lead Drug Gets Fast Track Designation by FDA

May 29, 2020
Report ID: 11493
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Cardiff Oncology Inc.
Cardiff Oncology Inc.
Healthcare
Biotechnology
Ticker
CRDF
Current Price
$2.7 -4.59%
Market Cap
$120.8M
Price Target
Refer to Report
Volume
537.6K
52wk Range
$0.94 - $6.42
Related Research Reports
5/29/2020

Lead Drug Gets Fast Track Designation by FDA
Lead Drug Gets Fast Track Designation by FDA (CRDF)
5/8/2020

New CEO, New Name, Still a Promising Cancer Drug
New CEO, New Name, Still a Promising Cancer Drug (CRDF)
4/29/2020

Lead Drug Shows Potential as KRAS inhibitor in Colorectal Cancer
Lead Drug Shows Potential as KRAS inhibitor in Colorectal Cancer (CRDF)
2/14/2020

Lead Drug Shows Efficacy in Difficult to Treat Prostate Cancer Patients
Lead Drug Shows Efficacy in Difficult to Treat Prostate Cancer Patients (CRDF)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy